News
Trump Administration Touts Pro-Life Changes, Spares Abortion Pill
Liberty Check
The Trump administration announced policy changes on fetal tissue and embryonic stem cell research to coincide with the March for Life, aiming to address pro-life criticism of Biden-era abortion pill policies. While defunding research tied to elective abortions, the administration preserved access to mifepristone, prompting backlash from major pro-life organizations and activists.
- NIH ended funding for research involving fetal tissue from elective abortions and paused new embryonic stem cell line submissions, citing scientific advances and ethical demands.
- The Department of Health and Human Services highlighted new guidance reinforcing conscience protections for healthcare providers opposed to abortion-related practices.
- Pro-life leaders and activists criticized the administration for not reversing expanded access to abortion pills, noting a steep rise in medication abortions since 2022.
The fight over abortion policy remains heated, and the need for vigilance is greater than ever. Constitutional conservatives must hold elected officials accountable and defend conscience rights for medical professionals and citizens alike.
Our freedoms depend on staying vigilant.
